| Thursday, November 16, 2023 |
Morgan Lewis’s Ninth Annual Research & Development Tax Credit Symposium will focus on the latest developments impacting the research and development (R&D) tax credit under Internal Revenue Code Section 41 and the treatment of research or experimental expenditures under Section 174, as amended. We will discuss best practices for identifying and documenting your qualified research expenses (QREs) and research and experimentation (R&E) expenditures and defending R&D positions on audit. The symposium is designed for corporate tax executives, directors, managers, accountants, and other tax professionals who assist companies that have activities and costs eligible for the research credit and/or subject to the new rules for R&E expenditures.
Who Should Attend: Although the research credit is often thought of in connection with companies in the high-tech, pharmaceutical, and biotechnology industries, it is certainly not limited to those industries.
Companies in a wide array of industries can reap substantial financial benefits from R&D tax incentives when they invest in research to make lighter, stronger, cheaper, or more reliable products; design more economical and versatile internal processes; or develop new customer-interfacing or internal software programs. In addition, with the mandatory capitalization and amortization regime under Section 174, companies in all industries must identify costs constituting R&E expenditures subject to the new accounting rules.
Other industries benefiting from the research credit include:
Dinner will be held the evening before each program—all registrants are invited to attend.
Please contact symposium co-chairs Alex Sadler and Doug Norton, or marketing and communications assistant Sabrina Tredwell with any questions.